Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EQ504 SAD, MAD, and Food Effect Study in Healthy Volunteers
NCT07869225Phase 1Not yet recruiting
- Sponsor
- Equillium, Inc.
- Start
- Oct 2026
- Primary completion
- Apr 2027
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of EQ504 in ulcerative colitis (UC) (4 arms), sponsored by Equillium, Inc. Primary endpoint: Incidence of Treatment Emergent Adverse Events at Day 17. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
EQ504
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT07869225.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07869225.